الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
SLE is a chronic inflammatory systemic autoimmune disease and is characterised by sustained abnormal immune activation and autoantibody production. A defect in the inhibitory molecules including CTLA4 is one possibility of the many different mechanisms that may contribute to the pathogenesis.
A soluble CTLA4 protein was found to be present in human serum. The presence of this soluble costimulatory molecule in human serum may provide a means for T-lymphocytes to either enhance or inhibit their biologic effects through additional crossing-linking or competitive blocking to their cell-bound counterparts, thereby in?uencing the T cell-mediated immune responses.
Aim of work:
The aim of this work is to study the role of sCTLA4 in SLE disease.
Subjects and methods:
Thirty four SLE patients and twelve normal subjects were subjected to measurement of serum level of sCTLA4 using enzyme linked immunesobent assay technique (ELISA).
Results
The serum level of sCTLA4 in the patients with active SLE was much higher than that in the healthy control and patients not in activity with high significant difference (P < 0.001). The level of sCTLA4 in addition showed weak positive correlation with levels of proteinuria(r=0.424, p=0.273).
Conclusion
Soluble CTLA4 can be used as a prognostic tool for detection of SLE activity